SPY765.80+0.02%QQQ737.05+0.07%BTC/USD82,936.69−0.62%DIA514.14+0.02%GLD378.31+0.11%TLT78.69+0.09%
Benzinga

Compass Therapeutics Inc

CMPXNASDAQ
Trade with Public
Trade with Public
$1.11
-0.02-1.77%
At close: Sep 28, 5:00 PM EST
$1.13
0.02081.87%
After Hours: 7:59 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Compass Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Compass Therapeutics (CMPX).

Price Target Range — 11 Quarters

Analyst Consensus — 15 Analysts

1S.Buy
13Buy
1Hold
Consensus RatingBuy# Analysts15Avg. Consensus PT$9Upside to Avg. PT+657.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 23, 2026Craig-HallumAlbert LowePT CutBuy$15→$8
Sep 23, 2026CitizensReni J. BenjaminPT CutMarket Outperform$10→$4
More with Benzinga EdgeGet Access

Analyst Ratings News

This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Wall Street analysts downgraded Rollins, Yum Brands, Alkami Technology, VICI Properties and Safehold, cutting targets for Rollins and Alkami.
Avi Kapoor

PRO
Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8

Craig-Hallum analyst Albert Lowe maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $15 to $8.
Benzinga Newsdesk

This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.
Avi Kapoor

PRO
Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4

Citizens analyst Reni J. Benjamin maintains Compass Therapeutics (NASDAQ:CMPX) with a Market Outperform and lowers the price target from $10 to $4.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4

Guggenheim analyst Michael Schmidt maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $8 to $4.
Benzinga Newsdesk

PRO
Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1

Wedbush analyst Robert Driscoll downgrades Compass Therapeutics (NASDAQ:CMPX) from Outperform to Neutral and lowers the price target from $5 to $1.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved